지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2017.1
- 수록면
- 60 - 69 (10page)
이용수
초록· 키워드
오류제보하기
Despite the rapidly increasing prevalence of non-alcoholic fatty liver disease (NAFLD) in type 2 diabetes (T2D), few treatment modalities are currently available. We investigated the hepatic effects of the novel thiazolidinedione (TZDs), lobeglitazone (Duvie) in T2D patients with NAFLD. We recruited drug-naïve or metformin-treated T2D patients with NAFLD to conduct a multicenter, prospective, open-label, exploratory clinical trial. Transient liver elastography (Fibroscan®; Echosens, Paris, France) with controlled attenuation parameter (CAP) was used to non-invasively quantify hepatic fat contents. Fifty patients with CAP values above 250 dB/m were treated once daily with 0.5 mg lobeglitazone for 24 weeks. The primary endpoint was a decline in CAP values, and secondary endpoints included changes in components of glycemic, lipid, and liver profiles. Lobeglitazone-treated patients showed significantly decreased CAP values (313.4 dB/m at baseline vs. 297.8 dB/m at 24 weeks; P = 0.016), regardless of glycemic control. Lobeglitazone improved HbA1C values (7.41% [57.5 mM] vs. 6.56% [48.2 mM]; P < 0.001), as well as the lipid and liver profiles of the treated patients. Moreover, multivariable linear regression analysis showed that hepatic fat reduction by lobeglitazone was independently associated with baseline values of CAP, liver stiffness, and liver enzymes, and metformin use. Lobeglitazone treatment reduced intrahepatic fat content, as assessed by transient liver elastography, and improved glycemic, liver, and lipid profiles in T2D patients with NAFLD. Further randomized controlled trials using liver histology as an end point are necessary to evaluate the efficacy of lobeglitazone for NAFLD treatment (Clinical trial No. NCT02285205).
목차
등록된 정보가 없습니다.
참고문헌 (35)
참고문헌 신청
Wang YC / 2011 / Health and economic burden of the projected obesity trends in the USA and the UK / Lancet 378:815~825
류혜진 / 2015 / Hepatokines as a Link between Obesity and Cardiovascular Diseases / Diabetes and Metabolism Journal 39(1):10~15
박성근 / 2016 / The Risk of Abdominal Obesity according to the Degree of Non- Alcoholic Fatty Liver Disease in Korean Men / Journal of Korean Medical Science 31(3):410~416
Lee YH / 2014 / Non-laboratory-based self-assessment screening score for non-alcoholic fatty liver disease: development, validation and comparison with other scores / PLoS One 9:e107584
Chalasani N / 2012 / The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association / Hepatology 55:2005~2023
류혜진 / 2015 / Hepatokines as a Link between Obesity and Cardiovascular Diseases / Diabetes and Metabolism Journal 39(1):10~15
박성근 / 2016 / The Risk of Abdominal Obesity according to the Degree of Non- Alcoholic Fatty Liver Disease in Korean Men / Journal of Korean Medical Science 31(3):410~416
Lee YH / 2014 / Non-laboratory-based self-assessment screening score for non-alcoholic fatty liver disease: development, validation and comparison with other scores / PLoS One 9:e107584
Chalasani N / 2012 / The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association / Hepatology 55:2005~2023
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
A Real-World Study of Long-Term Safety and Efficacy of Lobeglitazone in Korean Patients with Type 2 Diabetes Mellitus
Diabetes and Metabolism Journal
2022 .11
-
Effects of Lobeglitazone, a Novel Thiazolidinedione, on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus over 52 Weeks
Diabetes and Metabolism Journal
2017 .01
-
Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus
Diabetes and Metabolism Journal
2021 .01
-
Effects of Lobeglitazone, a New Thiazolidinedione, on Osteoblastogenesis and Bone Mineral Density in Mice
Endocrinology and Metabolism
2017 .01
-
Identification of high-risk subjects in nonalcoholic fatty liver disease
Clinical and Molecular Hepatology
2023 .02
-
Application of transient elastography in nonalcoholic fatty liver disease
Clinical and Molecular Hepatology
2020 .01
-
Lobeglitazone attenuates allergic inflammatory response on asthmatic murine model induced by ovalbumin
한국실험동물학회 학술발표대회 논문집
2019 .01
-
Nonalcoholic fatty liver disease and non-liver comorbidities
Clinical and Molecular Hepatology
2023 .02
-
Acute hepatitis A; Cytotoxic T lymphocyte-associated antigen 4; Programmed death 1
Gut and Liver
2016 .01
-
Non-alcoholic fatty liver disease-related hepatocellular carcinoma
Journal of Liver Cancer
2023 .03
-
Effects of Metformin on Hepatic Steatosis in Adults with Nonalcoholic Fatty Liver Disease and Diabetes: Insights from the Cellular to Patient Levels
Gut and Liver
2021 .11
-
Severe Phenotype of Non-alcoholic Fatty Liver Disease in Pediatric Patients with Subclinical Hypothyroidism: a Retrospective Multicenter Study from Korea
Journal of Korean Medical Science
2021 .01
-
Liver
대한외과학회 학술대회 초록집
2016 .11
-
Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment
Diabetes and Metabolism Journal
2019 .01
-
Risk factors in nonalcoholic fatty liver disease
Clinical and Molecular Hepatology
2023 .02
-
Lobeglitazone, a Novel Peroxisome Proliferator-Activated Receptor γ Agonist, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice
Endocrinology and Metabolism
2017 .01
-
Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future
Clinical and Molecular Hepatology
2023 .02
-
Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future
Clinical and Molecular Hepatology
2023 .02
-
Non-alcoholic fatty liver disease: the pathologist’s perspective
Clinical and Molecular Hepatology
2023 .02
-
Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease
Clinical and Molecular Hepatology
2023 .02
이 논문의 저자 정보
최근 본 자료
댓글(0)
0